Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 open-label safety study of E/C/F/TAF single-tablet regimen in HIV-1 patients with mild to moderate renal impairment
NL-OMON41597Phase 3Active, not recruiting
- Sponsor
- Gilead Sciences
- Start
- Nov 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide in Human immunodeficiency virus infection type 1, sponsored by Gilead Sciences. Primary endpoints: Renal parameters at Week 24 and Renal safety assessments. Started Nov 2013; status: active, not recruiting.
02
Drugs
elvitegravircobicistatemtricitabinetenofovir alafenamide
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on NL-OMON41597.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41597.